Argenx

Update in progress

ARGX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

argenx SE is a commercial-stage biopharma company focused on autoimmune diseases, operating in the US, Japan, China, the Netherlands, and globally. It markets VYVGART for generalized MG and ITP, and VYVGART HYTRULO for MG and CIDP. It also develops efgartigimod for several autoimmune conditions and a broad ARGX portfolio plus empasiprubart and adimanebart. Partnerships include Zai Lab, Halozyme, OncoVerity, and AbbVie. Based in Amsterdam, founded 2008.

Company score

Sentiment: 0.67; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.59; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.21; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.44; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive